Madrigal Pharmaceuticals, Inc. MDGL Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s other accrued liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported other accrued liabilities of $36.99M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s other accrued liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s other accrued liabilities increased by 182.1% year-over-year, from $13.11M to $36.99M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s other accrued liabilities?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s other accrued liabilities has grown at a 52.0% compound annual growth rate (CAGR), from $4.16M to $33.74M.